RATIONALE: Inhaled nitric oxide (iNO) can reverse neonatal pulmonary hypertension and bronchoconstriction and reduce proliferation of cultured arterial and airway smooth muscle cells. OBJECTIVES: To see if continuous iNO from birth might reduce pulmonary vascular and respiratory tract resistance (PVR, RE) and attenuate growth of arterial and airway smooth muscle in preterm lambs with chronic lung disease. METHODS: Eight premature lambs received mechanical ventilation for 3 weeks, four with and four without iNO (5-15 ppm). Four term lambs, mechanically ventilated without iNO for 3 weeks, served as additional control animals. MEASUREMENTS: PVR and RE were measured weekly. After 3 weeks, lung tissue was processed for quantitative image analysis of smooth muscle abundance around small arteries (SMart) and terminal bronchioles (SMtb). Radial alveolar counts were done to assess alveolar number. Endothelial NO synthase (eNOS) protein in arteries and airways was measured by immunoblot analysis. MAIN RESULTS: At study's end, PVR was similar in iNO-treated and untreated preterm lambs; PVR was less in iNO-treated preterm lambs compared with term control animals. RE in iNO-treated lambs was less than 40% of RE measured in preterm control animals. SMart was similar in iNO-treated and both groups of control lambs; SMtb in lambs given iNO was significantly less (approximately 50%) than in preterm control animals. Radial alveolar counts of iNO-treated lambs were more than twice that of preterm control animals. eNOS was similar in arteries and airways of iNO-treated preterm lambs compared with control term lambs. CONCLUSIONS: iNO preserves structure and function of airway smooth muscle and enhances alveolar development in preterm lambs with chronic lung disease.
RATIONALE: Inhaled nitric oxide (iNO) can reverse neonatal pulmonary hypertension and bronchoconstriction and reduce proliferation of cultured arterial and airway smooth muscle cells. OBJECTIVES: To see if continuous iNO from birth might reduce pulmonary vascular and respiratory tract resistance (PVR, RE) and attenuate growth of arterial and airway smooth muscle in preterm lambs with chronic lung disease. METHODS: Eight premature lambs received mechanical ventilation for 3 weeks, four with and four without iNO (5-15 ppm). Four term lambs, mechanically ventilated without iNO for 3 weeks, served as additional control animals. MEASUREMENTS: PVR and RE were measured weekly. After 3 weeks, lung tissue was processed for quantitative image analysis of smooth muscle abundance around small arteries (SMart) and terminal bronchioles (SMtb). Radial alveolar counts were done to assess alveolar number. Endothelial NO synthase (eNOS) protein in arteries and airways was measured by immunoblot analysis. MAIN RESULTS: At study's end, PVR was similar in iNO-treated and untreated preterm lambs; PVR was less in iNO-treated preterm lambs compared with term control animals. RE in iNO-treated lambs was less than 40% of RE measured in preterm control animals. SMart was similar in iNO-treated and both groups of control lambs; SMtb in lambs given iNO was significantly less (approximately 50%) than in preterm control animals. Radial alveolar counts of iNO-treated lambs were more than twice that of preterm control animals. eNOS was similar in arteries and airways of iNO-treated preterm lambs compared with control term lambs. CONCLUSIONS: iNO preserves structure and function of airway smooth muscle and enhances alveolar development in preterm lambs with chronic lung disease.
Authors: William M Maniscalco; Richard H Watkins; Gloria S Pryhuber; Abhay Bhatt; Colleen Shea; Heidie Huyck Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-04 Impact factor: 5.464
Authors: R D Bland; K H Albertine; D P Carlton; L Kullama; P Davis; S C Cho; B I Kim; M Dahl; N Tabatabaei Journal: Pediatr Res Date: 2000-07 Impact factor: 3.756
Authors: A N MacRitchie; K H Albertine; J Sun; P S Lei; S C Jensen; A A Freestone; P M Clair; M J Dahl; E A Godfrey; D P Carlton; R D Bland Journal: Am J Physiol Lung Cell Mol Physiol Date: 2001-10 Impact factor: 5.464
Authors: Shari M Leuwerke; Aditya K Kaza; Curtis G Tribble; Irving L Kron; Victor E Laubach Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-06 Impact factor: 5.464
Authors: A J Bhatt; G S Pryhuber; H Huyck; R H Watkins; L A Metlay; W M Maniscalco Journal: Am J Respir Crit Care Med Date: 2001-11-15 Impact factor: 21.405
Authors: M Jakkula; T D Le Cras; S Gebb; K P Hirth; R M Tuder; N F Voelkel; S H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-09 Impact factor: 5.464
Authors: Lisa M Askie; Roberta A Ballard; Gary R Cutter; Carlo Dani; Diana Elbourne; David Field; Jean-Michel Hascoet; Anna Maria Hibbs; John P Kinsella; Jean-Christophe Mercier; Wade Rich; Michael D Schreiber; Pimol Srisuparp Wongsiridej; Nim V Subhedar; Krisa P Van Meurs; Merryn Voysey; Keith Barrington; Richard A Ehrenkranz; Neil N Finer Journal: Pediatrics Date: 2011-09-19 Impact factor: 7.124
Authors: Anne Hilgendorff; Irwin Reiss; Harald Ehrhardt; Oliver Eickelberg; Cristina M Alvira Journal: Am J Respir Cell Mol Biol Date: 2014-02 Impact factor: 6.914
Authors: Virender K Rehan; Jeanette Fong; Robert Lee; Reiko Sakurai; Zheng-Ming Wang; Mar Janna Dahl; Robert H Lane; Kurt H Albertine; John S Torday Journal: Pediatr Res Date: 2011-11 Impact factor: 3.756
Authors: Brent Reyburn; Marlana Li; Drew B Metcalfe; Nicholas J Kroll; Jeremy Alvord; Albert Wint; Mar Janna Dahl; Jiancheng Sun; Li Dong; Zheng-Ming Wang; Christopher Callaway; Robert A McKnight; Laurie Moyer-Mileur; Bradley A Yoder; Donald M Null; Robert H Lane; Kurt H Albertine Journal: Am J Respir Crit Care Med Date: 2008-06-12 Impact factor: 21.405
Authors: Lisa M Askie; Roberta A Ballard; Gary Cutter; Carlo Dani; Diana Elbourne; David Field; Jean-Michel Hascoet; Anna Maria Hibbs; John P Kinsella; Jean-Christophe Mercier; Wade Rich; Michael D Schreiber; Pimol Srisuparp; Nim V Subhedar; Krisa P Van Meurs; Merryn Voysey; Keith Barrington; Richard A Ehrenkranz; Neil Finer Journal: BMC Pediatr Date: 2010-03-23 Impact factor: 2.125